BB's Stock Haven

[Helter Skelter]

$SNGX +175% @ 3.80...now +230% moving FAST on NEWS/volume premarket...

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire   "Press Releases US - English"

Results Confirm and Extend Response Results from Phase 3 FLASH Study

PRINCETON, N.J. , May 4, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ( Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a compatibility study evaluating HyBryte (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device, which recently received 510(k) clearance from U.S. Food and Drug Administration (FDA). The open-label study (protocol HPN-CTCL-02) enrolled 9 patients to receive 8 weeks of HyBryte treatment of their cancerous lesions, with an assessment of treatment response conducted at week 10 using the Composite Assessment of Index Lesion Severity (CAILS) score. All subjects were enrolled by Brian Poligone , MD, PhD, at the Rochester Skin Lymphoma Medical Group .